How well does Enasidenib(Avatrombopag) work?

How well the drug worked in clinical studies.

Clinical Efficacy

In clinical trials for chronic liver disease patients, a significantly higher proportion of DOPTELET-treated patients avoided the need for platelet transfusion or rescue procedures for bleeding compared to placebo before their scheduled procedure. In adults with chronic immune thrombocytopenia, DOPTELET-treated patients had a significantly greater cumulative number of weeks with platelet counts ≥50×10⁹/L without rescue therapy over a 6-month period compared to placebo. Similarly, in pediatric patients with immune thrombocytopenia, DOPTELET was superior to placebo in achieving durable platelet responses.